Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT

Annals of Nuclear Medicine

Volumn 22, Issue 2, 2008, Pages 133-137

  Toshikuni, Nobuyuki ^a,b   Kai, Kyohei ^a   Fujisawa, Masayoshi ^a  

^a HIMEJI RED CROSS HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

18F FDG PET CT; Nonfunctioning endocrine tumor; Pancreas

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLIBENCLAMIDE; TRACER;

AGED; ANAMNESIS; ARTICLE; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ENDOCRINE TUMOR; FEMALE; HISTOLOGY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS RESECTION; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPLENECTOMY;

AGED; DIABETES MELLITUS, TYPE 2; FATIGUE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; PANCREAS; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 40149107432     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-007-0085-0     Document Type: Article

References (23)

1. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781.
2. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345-352.
3. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Itoh K, Imamura M, et al. Evaluation of pancreatic islet cell tumors by fluorine-18 fluorodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 2000;25:115-119.
4. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83.
5. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology 2006;238:405-422.
6. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, et al. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006;11:286-296.
7. Procacci C, Carbognin G, Accordini S, Biasiutti C, Bicego E, Romano L, et al. Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol 2001;11:1175-1183.
8. Rodallec M, Vilgrain V, Zins M, Couvelard A, Ruszniewski P, Menu Y. Helical CT of pancreatic endocrine tumors. J Comput Assist Tomogr 2002;26:728-733.
9. Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005;19:195-211.
10. Herwick S, Miller FH, Keppke AL. MRI of islet cell tumors of the pancreas. AJR Am J Roentgenol 2006;187:W472-480.
11. Rosch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721-1726.
12. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
13. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853-858.
14. Eriksson B, Bergstrom M, Sundin A, Juhlin C, Orlefors H, Oberg K, et al. The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci 2002;970:159-169.
15. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507.
16. Cohade C, Osman M, Leal J, Wahl RL. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003;44:1797-1803.
17. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al. Delayed (18)F-fluoro-2-deoxy-d-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000;89:2547-2554.
18. Buetow PC, Parrino TV, Buck JL, Pantongrag-Brown L, Ros PR, Dachman AH, et al. Islet cell tumors of the pancreas: pathologic-imaging correlation among size, necrosis and cysts, calcification, malignant behavior, and functional status. AJR Am J Roentgenol 1995;165:1175-1179.
19. Sugiyama M, Abe N, Izumisato Y, Yamaguchi Y, Yamato T, Tokuhara M, et al. Differential diagnosis of benign versus malignant nonfunctioning islet cell tumors of the pancreas: the roles of EUS and ERCP. Gastrointest Endosc 2002;55:115-119.
20. Rodallec M, Vilgrain V, Couvelard A, Rufat P, O'Toole D, Barrau V, et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 2006;6:77-85.
21. Nakata B, Chung YS, Nishimura S, Nishihara T, Sakurai Y, Sawada T, et al. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997;79:695-699.
22. Koyama K, Okamura T, Kawabe J, Nakata B, Chung KH, Ochi H, et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001;15:217-224.
23. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998;39:1030-1033.